Pierre I. Karakiewicz
Université de Montréal
CancerInternal medicineUrologySurgeryOncologyLogistic regressionStage (cooking)Hazard ratioCystectomyRenal cell carcinomaProstatectomyProstate cancerNephrectomyBladder cancerLymph nodePopulationIn patientNomogramProportional hazards modelMedicineCohort
1,524Publications
116H-index
35.3kCitations
Publications 1568
Newest
#1M. Wenzel (UdeM: Université de Montréal)
#2Claudia Collà Ruvolo (University of Naples Federico II)H-Index: 3
Last. Andreas BeckerH-Index: 4
view all 13 authors...
Abstract null null Background null Intermediate risk (IR) prostate cancer (PCa) is a highly heterogeneous entity and can be distinguished into favorable and unfavorable IR PCa according to biopsy, PSA and cT-stage characteristics. These differences may translate into differences in treatment type. null null null Methods null We tested for differences in PCa tumor characteristics and differences in active treatment rates (radical prostatectomy [RP], external beam radiotherapy [EBRT]) according to...
Source
#1Alberto MartiniH-Index: 27
#2G.O. CirulliH-Index: 3
Last. John P. SfakianosH-Index: 26
view all 15 authors...
Source
#1Ivan LysenkoH-Index: 5
#2David D'AndreaH-Index: 16
Last. Shahrokh F. ShariatH-Index: 132
view all 10 authors...
Source
Source
#1Elio MazzoneH-Index: 11
#2Giorgio GandagliaH-Index: 47
Last. R. Jeffrey KarnesH-Index: 70
view all 25 authors...
Source
#1Luigi NoceraH-Index: 5
Last. R. LeniH-Index: 1
view all 20 authors...
Source
INTRODUCTION AND OBJECTIVE:An increase in the rates of high-risk prostate cancer (PCa) was recently reported. We tested the association between number of prostate biopsy cores and low, intermediate...
Source
#2Fahad QuhalH-Index: 1
Last. Shahrokh F. ShariatH-Index: 132
view all 7 authors...
Source
#2Luigi NoceraH-Index: 5
Last. Hartwig HulandH-Index: 94
view all 12 authors...
Source
#1Fahad QuhalH-Index: 1
#2Paweł RajwaH-Index: 4
Last. Paolo GonteroH-Index: 52
view all 15 authors...
Source